•General and administrative expenses increased $163 million or 11% driven by acquisition-related expenses and investments in corporate functions. General and administrative included a favorable foreign currency impact of 2%. Operating income increased $2.0 billion or 10% driven by growth in Productivit...
• Operating expenses increased by +30% YOY to reach EGP 8,910 million for FY24, reflecting improved efficiency that reached 16.8% by the end of Dec-24, down by -147 bps YOY. • Provision expense, QNB made sure to cover the necessary need. Charges for expected credit losses (ECL) ...
Increased site expenses to support design, management and delivery of ourChildressoperations Includes$6.3 millionprovision for Canadian non-refundable sales tax Net loss after income tax of$29.0 million, as compared to a loss of$171.9 millionin fiscal year 2023 Operating cash inflow of$52.7 million,...
Administrative expenses (excluding depreciation & amortisation) (8,884) (9,928) EBITDA 3,860 11,295 Amortisation of development costs
Operating EBIT: operating profit/(loss) before other expenses (strategic and restructuring expenses, litigation expenses and impairment and disposal of assets expenses) In accordance with IFRS 5 (Non-current Assets Held for Sale and Discontinued Operations), net loss from discontinued operatio...
In the second quarter of fiscal year 2023, Microsoft recorded costs related to decisions announced on January 18th, 2023, including employee severance expenses, impairment charges resulting from changes to our hardware portfolio, and costs related to lease consolidation activities. Microsoft has provided...
For the year 2024, profit before income tax surged 552.5 percent to $743.9 million from $114.0 million a year ago as a result of higher gross profit and lower administrative and exploration expenses. Income tax was $390.2 million in the year, compared to tax income of $205.0 mill...
Corporate and other expenses (153,981 ) (401 ) (154,382 ) Interest expense, net (54,707 ) — (54,707 ) Loss before income taxes $ (409,639 ) $ (2,167 ) $ (411,806 ) Diluted earnings (loss) per share growth (94 )% (1 )% (95 )% Con...
Net Profit (before exceptional items) at Rs 1,030 Cr, Up 31% Biosimilars Revenue in FY24 Crosses USD 1 Bn Bengaluru, Karnataka, India: May 16, 2024: Biocon Limited(BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial...
Create a free Seeking Alpha account to access breaking news and valuable research tools »Create Free AccountSeeking Alpha - Power to Investors Power to Investors Follow us Download app Account Account Login Manage My Portfolio Privacy Create Portfolio Portfolio Health Check Alert...